for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alkem Laboratories Ltd

ALKE.NS

Latest Trade

2,329.70INR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1,660.00

 - 

2,405.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Latest Developments

Alkem Laboratories Ltd -Enters Into Asset Purchase Agreement With Abbvie Inc., USA

Dec 31 (Reuters) - Abbvie Inc <ABBV.N>::ALKEM LABORATORIES LTD -ENTERED INTO AN ASSET PURCHASE AGREEMENT DATED 30TH DECEMBER, 2019 WITH ABBVIE INC., USA.ALKEM LABORATORIES LTD -AGREEMENT FOR ACQUISITION OF CERTAIN ASSETS RELATED TO ACTIVE PHARMACEUTICAL INGREDIENT, DRONABINOL.ALKEM LABORATORIES LTD - COST OF ACQUISITION $10 MILLION PLUS SUITABLE WORKING CAPITAL ADJUSTMENTS ON CLOSING.

India's Alkem Laboratories Sept Quarter Consol Profit Rises

Nov 11 (Reuters) - Alkem Laboratories Ltd <ALKE.NS>::SEPT QUARTER CONSOL NET PROFIT 3.71 BILLION RUPEES VERSUS 2.54 BILLION RUPEES YEAR AGO.SEPT QUARTER CONSOL REVENUE FROM OPERATIONS 22.64 BILLION RUPEES VERSUS 19.19 BILLION RUPEES YEAR AGO.

Alkem Laboratories Says Closure Of US FDA Inspection At Manufacturing Facilities Located At Daman And Baddi

Nov 1 (Reuters) - Alkem Laboratories Ltd <ALKE.NS>::ALKEM LABORATORIES LTD SAYS CLOSURE OF US FDA INSPECTION AT ALKEM'S MANUFACTURING FACILITIES LOCATED AT DAMAN, INDIA AND BADDI, INDIA..ALKEM LABORATORIES -US FDA ISSUED ESTABLISHMENT INSPECTION REPORT FOR MANUFACTURING FACILITY AT DAMAN WHICH WAS INSPECTED FROM 26TH AUGUST TO AUG 30.

India's Alkem Labs Says No Form 483 Issued After FDA Inspection at Taloja

Oct 22 (Reuters) - Alkem Laboratories Ltd <ALKE.NS>::INDIA'S ALKEM LABS SAYS US FDA HAD CONDUCTED AN INSPECTION AT COMPANY'S BIOEQUIVALENCE CENTER LOCATED AT TALOJA, MAHARASHTRA; NO FORM 483 ISSUED.

India's Alkem Labs St. Louis Plant Gets FDA Form 483 With 4 Observations

Sept 11 (Reuters) - Alkem Laboratories Ltd <ALKE.NS>::INDIA'S ALKEM LABS SAYS US FDA HAS ISSUED AN ESTABLISHMENT INSPECTION REPORT FOR COMPANY'S MANUFACTURING FACILITY LOCATED AT ST. LOUIS.SAYS RECEIVED A FORM 483 ISSUED BY US FDA CONTAINING FOUR OBSERVATIONS.SAYS INSPECTION HAS NOW BEEN CLOSED BY US FDA.

India's Alkem Labs Says Got U.S. FDA Form 483 With Two Observations For Daman Unit

Aug 30 (Reuters) - Alkem Laboratories Ltd <ALKE.NS>::SAYS US FDA HAD CONDUCTED AN INSPECTION AT COMPANY'S MANUFACTURING FACILITY LOCATED AT DAMAN, INDIA.SAYS COMPANY HAS RECEIVED A FORM 483 WITH TWO (2) OBSERVATIONS.SAYS SHALL PUT TOGETHER A RESPONSE WITH ADEQUATE CORRECTIVE AND PREVENTIVE MEASURES TO ADDRESS US FDA OBSERVATIONS.

India's Alkem Laboratories June-Qtr Consol Net Profit Rises

Aug 12 (Reuters) - Alkem Laboratories Ltd <ALKE.NS>::JUNE QUARTER CONSOL NET PROFIT 1.85 BILLION RUPEES VERSUS 1.36 BILLION RUPEES YEAR AGO.JUNE QUARTER CONSOL REVENUE FROM OPERATIONS 18.50 BILLION RUPEES VERSUS 16.59 BILLION RUPEES YEAR AGO.

India's Alkem Laboratories March-Qtr Consol Net Profit Rises

May 30 (Reuters) - Alkem Laboratories Ltd <ALKE.NS>::MARCH QUARTER CONSOL NET PROFIT 1.67 BILLION RUPEES VERSUS 670.8 MILLION RUPEES YEAR AGO.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 18.54 BILLION RUPEES VERSUS 14.92 BILLION RUPEES YEAR AGO.RECOMMENDED FINAL DIVIDEND OF 8 RUPEES PER SHARE.APPROVED RE-APPOINTMENT OF SAMPRADA SINGH AS CHAIRMAN EMERITUS.APPROVED RE-APPOINTMENT OF BASUDEO N. SINGH AS EXECUTIVE CHAIRMAN.

Alkem Labs Says Product Not Being Made At This Time At St Louis Facilty as it Awaits USFDA approval

March 22 (Reuters) - Alkem Laboratories Ltd <ALKE.NS>::ALKEM LABORATORIES -SUBMITTED RESPONSE TO THE 8 FORM 483 OBSERVATIONS RECEIVED DURING PRE-APPROVAL INSPECTION FOR PRODUCT AT FACILITY AT ST. LOUIS.ALKEM LABORATORIES - SAID PRODUCT IS NOT BEING MANUFACTURED AT THIS TIME AS IT IS AWAITING APPROVAL FROM US FDA..

India's Alkem Laboratories Dec Quarter Consol Net Profit Rises

Feb 8 (Reuters) - Alkem Laboratories Ltd <ALKE.NS>::DEC QUARTER CONSOL REVENUE FROM OPERATIONS 19.25 BILLION RUPEES VERSUS 17.41 BILLION RUPEES YEAR AGO.DECLARED INTERIM DIVIDEND OF 8 RUPEES PER SHARE.DEC QUARTER CONSOL NET PROFIT 2.03 BILLION RUPEES VERSUS PROFIT 1.72 BILLION RUPEES YEAR AGO.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up